Editorial: Unraveling the links between nutrients and metabolic dysfunction-associated liver disease: insights and implications

Editorial: Unraveling the links between nutrients and metabolic dysfunction-associated liver disease: insights and implications

Saved in:

Bibliographic Details
Main Authors:	Bruno Ramos-Molina, Claudia Tovar-Palacio, Ivan Torre-Villalvazo, Md. Wasim Khan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Nutrition
Subjects:	MASLD metabolic dysfunction associated steatotic liver disease MASH and liver fibrosis nutrition lifestyle biochemistry and metabolism
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2024.1525180/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Miwa Kawanaka, et al.
Published: (2024-01-01)

Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience
by: Thanikan Sukaram, et al.
Published: (2025-01-01)

Effect of a Ketogenic Diet on Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yeo-Wool Kang, et al.
Published: (2024-11-01)

Statin Use in Metabolic Dysfunction-Associated Steatotic Liver Disease and Effects on Vibration-Controlled Transient Elastography-Derived Scores—A Population-Based Inverse Probability Treatment Weighting Analysis
by: Natchaya Polpichai, et al.
Published: (2024-12-01)

The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data
by: Haijun Ma, et al.
Published: (2025-01-01)

Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
by: Felicianna, et al.
Published: (2024-12-01)

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
by: Sanad Dawod, et al.
Published: (2024-11-01)

An epidemiological study on the factors including genetic polymorphism influencing ALT >30 U/L and liver fibrosis progression in metabolic dysfunction‐associated steatotic liver disease among the general population
by: Satoshi Sato, et al.
Published: (2024-12-01)

An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease
by: Shahid Habib, et al.
Published: (2024-11-01)

FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
by: Mário Reis Álvares-da-Silva, et al.
Published: (2025-01-01)

Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease
by: WANG Ziqian, et al.
Published: (2024-07-01)

Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice
by: Gi Cheol Park, et al.
Published: (2024-10-01)

Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01)

Impact of liver graft steatosis on long-term post-transplant hepatic steatosis and fibrosis via magnetic resonance quantification
by: Lung-Yi Mak, et al.
Published: (2025-01-01)

Even moderate liver fat accumulation below conventional fatty liver cutoffs is linked to multiple metabolomic alterations and gestational dysglycemia in Asian women of reproductive age
by: Priti Mishra, et al.
Published: (2024-11-01)

Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females
by: Xiaoning Gan, et al.
Published: (2024-12-01)

Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD
by: Jesse Pustjens, et al.
Published: (2024-12-01)

The moderating effect of dietary fiber intake on the association between sleep pattern and liver fibrosis in metabolic dysfunction-associated steatotic liver disease: a study from NHANES
by: Guoqing Jia, et al.
Published: (2024-12-01)

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Julia Markowska, et al.
Published: (2024-11-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
by: Xin Qiu, et al.
Published: (2025-01-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

An Assessment of the Feasibility, Patient Acceptance, and Performance of Point-of-Care Transient Elastography for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis
by: Taranika Sarkar Das, et al.
Published: (2024-11-01)

The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease
by: Anna E. Płatek, et al.
Published: (2023-09-01)

Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease
by: Thaninee Prasoppokakorn, et al.
Published: (2024-12-01)

Role of waist circumference, body mass index and high-sensitivity C-reactive protein in pediatric steatotic liver disease: A cross-sectional study
by: Qiaoling Wu, et al.
Published: (2025-01-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease
by: Joana D’Arc Matos França de Abreu, et al.
Published: (2024-11-01)

Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease
by: Ahmed Mohamed ElGhandour, et al.
Published: (2024-11-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
by: Umasankari S., et al.
Published: (2024-12-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
by: Jeffrey V. Lazarus, et al.
Published: (2025-01-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Serum dihomo-g-linolenic acid concentration as a potential novel noninvasive biomarker for liver steatosis detection in children
by: Natalia Kopiczko, et al.
Published: (2024-12-01)

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
by: Caesar Ferrari, et al.
Published: (2024-10-01)

Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis
by: Isabel Omaña-Guzmán, et al.
Published: (2024-11-01)

Evaluation of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease using ultrasound controlled attenuation parameter combined with clinical features
by: LIU Chunyu, et al.
Published: (2024-10-01)

Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Xue Zou, et al.
Published: (2024-12-01)

Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) from a Young Age Due to a Rare Genetic Disorder, Familial Partial Lipodystrophy: A Case Report and Review of the Literature
by: Elena Vorona, et al.
Published: (2024-12-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)